BioCentury | Feb 25, 2013
Financial News

Cytomedix proposes private placement of units

...Units: 9.1 million Price prior: $0.66 Placement agent: Burrill Shares outstanding prior: 94.3 million Investors: Aldagen...
BioCentury | Oct 22, 2012
Clinical News

ALD-401: Interim Phase II data

...for a total enrollment of 100 patients. Cytomedix gained the product through its acquisition of Aldagen Inc....
BioCentury | May 21, 2012
Clinical News

ALD-401: Phase II ongoing

...60 patients per the study protocol. The company gained the product through its acquisition of Aldagen Inc....
BioCentury | Feb 13, 2012
Company News

Aldagen, Cytomedix deal

...acquired regenerative cell therapy play Aldagen in a stock deal valued at about $16 million. Aldagen...
...company. Aldagen withdrew an IPO in 2008 and then refiled in 2009. In July 2010, Aldagen...
...Aldagen. Cozen O'Conner and Hutchison Law Group were legal counsel to Cytomedix and Aldagen, respectively. Aldagen Inc....
BioCentury | Feb 9, 2012
Company News

Cytomedix acquires Aldagen

...cell therapy play Aldagen Inc. (Durham, N.C.) in a stock deal valued at about $16 million. Aldagen...
...deal, certain Aldagen investors purchased $5 million of Cytomedix's shares in a concurrent private placement. Aldagen...
...Wednesday. Aldagen withdrew an IPO in 2008 and then refiled in 2009. In July 2010, Aldagen...
BioCentury | Jun 13, 2011
Clinical News

ALD-401: Phase II started

...an intracarotid infusion of 3 mL ALD-401 given 13-19 days post-stroke in about 100 patients. Aldagen Inc....
BioCentury | May 16, 2011
Product Development

Stemming Stroke's Effects

...At least five companies are conducting preclinical studies of stem cell therapies to treat stroke: Aldagen Inc....
...Inc. , Cryo-Cell International Inc. , Neuralstem Inc. and StemCells Inc. Companies and Institutions Mentioned Aldagen Inc....
BioCentury | Apr 11, 2011
Finance

Second time no charm

...Cell therapeutic company Aldagen Inc. , which apparently is running very low on cash, last week withdrew...
...then refiled in 2009. In July 2010, Aldagen updated its filing to raise $40 million. Aldagen...
...from bone marrow expressing high levels of aldehyde dehydrogenase . But at March 31, 2010, Aldagen...
BioCentury | Apr 11, 2011
Financial News

Aldagen withdraws IPO

...Date announced: 4/5/11 Type: IPO Underwriters: Boenning & Scattergood Inc.; Ladenburg Thalmann; National Securities Note: Aldagen...
BioCentury | Apr 6, 2011
Financial News

Aldagen pulls IPO

...to market conditions. In July 2010, the company amended its IPO to raise $40 million. Aldagen...
Items per page:
1 - 10 of 72
BioCentury | Feb 25, 2013
Financial News

Cytomedix proposes private placement of units

...Units: 9.1 million Price prior: $0.66 Placement agent: Burrill Shares outstanding prior: 94.3 million Investors: Aldagen...
BioCentury | Oct 22, 2012
Clinical News

ALD-401: Interim Phase II data

...for a total enrollment of 100 patients. Cytomedix gained the product through its acquisition of Aldagen Inc....
BioCentury | May 21, 2012
Clinical News

ALD-401: Phase II ongoing

...60 patients per the study protocol. The company gained the product through its acquisition of Aldagen Inc....
BioCentury | Feb 13, 2012
Company News

Aldagen, Cytomedix deal

...acquired regenerative cell therapy play Aldagen in a stock deal valued at about $16 million. Aldagen...
...company. Aldagen withdrew an IPO in 2008 and then refiled in 2009. In July 2010, Aldagen...
...Aldagen. Cozen O'Conner and Hutchison Law Group were legal counsel to Cytomedix and Aldagen, respectively. Aldagen Inc....
BioCentury | Feb 9, 2012
Company News

Cytomedix acquires Aldagen

...cell therapy play Aldagen Inc. (Durham, N.C.) in a stock deal valued at about $16 million. Aldagen...
...deal, certain Aldagen investors purchased $5 million of Cytomedix's shares in a concurrent private placement. Aldagen...
...Wednesday. Aldagen withdrew an IPO in 2008 and then refiled in 2009. In July 2010, Aldagen...
BioCentury | Jun 13, 2011
Clinical News

ALD-401: Phase II started

...an intracarotid infusion of 3 mL ALD-401 given 13-19 days post-stroke in about 100 patients. Aldagen Inc....
BioCentury | May 16, 2011
Product Development

Stemming Stroke's Effects

...At least five companies are conducting preclinical studies of stem cell therapies to treat stroke: Aldagen Inc....
...Inc. , Cryo-Cell International Inc. , Neuralstem Inc. and StemCells Inc. Companies and Institutions Mentioned Aldagen Inc....
BioCentury | Apr 11, 2011
Finance

Second time no charm

...Cell therapeutic company Aldagen Inc. , which apparently is running very low on cash, last week withdrew...
...then refiled in 2009. In July 2010, Aldagen updated its filing to raise $40 million. Aldagen...
...from bone marrow expressing high levels of aldehyde dehydrogenase . But at March 31, 2010, Aldagen...
BioCentury | Apr 11, 2011
Financial News

Aldagen withdraws IPO

...Date announced: 4/5/11 Type: IPO Underwriters: Boenning & Scattergood Inc.; Ladenburg Thalmann; National Securities Note: Aldagen...
BioCentury | Apr 6, 2011
Financial News

Aldagen pulls IPO

...to market conditions. In July 2010, the company amended its IPO to raise $40 million. Aldagen...
Items per page:
1 - 10 of 72